BR112012029633A2 - vetores do parapoxvírus contendo antígeno do vírus da raiva. - Google Patents

vetores do parapoxvírus contendo antígeno do vírus da raiva.

Info

Publication number
BR112012029633A2
BR112012029633A2 BR112012029633A BR112012029633A BR112012029633A2 BR 112012029633 A2 BR112012029633 A2 BR 112012029633A2 BR 112012029633 A BR112012029633 A BR 112012029633A BR 112012029633 A BR112012029633 A BR 112012029633A BR 112012029633 A2 BR112012029633 A2 BR 112012029633A2
Authority
BR
Brazil
Prior art keywords
rabies virus
virus antigen
vectors containing
parapoxvirus
containing rabies
Prior art date
Application number
BR112012029633A
Other languages
English (en)
Other versions
BR112012029633A8 (pt
Inventor
Nanda Kumar Damavarapu Reddy
Oliver Michel Martinon
Original Assignee
Ah Usa 42 Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ah Usa 42 Llc filed Critical Ah Usa 42 Llc
Publication of BR112012029633A2 publication Critical patent/BR112012029633A2/pt
Publication of BR112012029633A8 publication Critical patent/BR112012029633A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

vetores do parapoxvírus contendo antígeno do vírus da raiva - a presente invenção refere-se a parapoxvírus recombinantes os quais carregam em seus genomas compreendendo dna heterólogo derivado de um vírus da raiva, para a preparação de tais constructos, e a sua aplicação em composições imunogênicas e vacinas. adicionalmente se refere à aplicação de parapoxvírus recombinantes para diagnóstico.
BR112012029633A 2010-05-21 2011-04-27 Vetores do parapoxvírus contendo antígeno do vírus da raiva. BR112012029633A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34698810P 2010-05-21 2010-05-21
US41428710P 2010-11-16 2010-11-16
PCT/IB2011/051847 WO2011145013A1 (en) 2010-05-21 2011-04-27 Parapoxvirus vectors containing rabies virus antigen

Publications (2)

Publication Number Publication Date
BR112012029633A2 true BR112012029633A2 (pt) 2016-09-20
BR112012029633A8 BR112012029633A8 (pt) 2017-12-05

Family

ID=44972661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029633A BR112012029633A8 (pt) 2010-05-21 2011-04-27 Vetores do parapoxvírus contendo antígeno do vírus da raiva.

Country Status (17)

Country Link
US (1) US20110287051A1 (pt)
EP (1) EP2571521A1 (pt)
JP (1) JP5890399B2 (pt)
KR (2) KR20150015551A (pt)
CN (1) CN103260644A (pt)
AR (1) AR081409A1 (pt)
AU (1) AU2011254315B2 (pt)
BR (1) BR112012029633A8 (pt)
CA (1) CA2798055C (pt)
CL (1) CL2012003219A1 (pt)
CO (1) CO6670515A2 (pt)
MX (1) MX338052B (pt)
NZ (1) NZ603431A (pt)
RU (1) RU2545694C2 (pt)
UY (1) UY33400A (pt)
WO (1) WO2011145013A1 (pt)
ZA (1) ZA201208264B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014116334A1 (de) * 2014-11-10 2016-05-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Herstellung von rekombinanten Expressionsvektoren
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
EP3432922B1 (en) * 2016-03-21 2020-02-19 South Dakota Board of Regents Orf virus-based platform for vaccine delivery
CN111944769B (zh) * 2020-08-10 2022-06-28 塔里木大学 一种狂犬病毒g蛋白-羊痘病毒重组疫苗的构建方法
US20230340424A1 (en) * 2020-08-13 2023-10-26 Suzhou Prajna Biotech Co., Ltd. Mutant orf viruses and uses thereof
CN117298263A (zh) * 2023-09-27 2023-12-29 成都迈科康生物科技有限公司 一种重组狂犬病疫苗及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
CA2247336C (en) * 1996-02-28 2008-06-17 Bayer Aktiengesellschaft Parapoxviruses containing foreign dna, their production and their use in vaccines
WO2003050135A2 (en) * 2001-12-07 2003-06-19 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
ATE300954T1 (de) 2001-12-10 2005-08-15 Bavarian Nordic As Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung
WO2010050913A1 (en) * 2008-10-31 2010-05-06 The Brigham And Women's Hospital, Inc. Vaccination with poxvirus vectors via mechanical epidermal disruption

Also Published As

Publication number Publication date
KR20150015551A (ko) 2015-02-10
KR20130008645A (ko) 2013-01-22
US20110287051A1 (en) 2011-11-24
RU2012149036A (ru) 2014-06-27
AU2011254315A1 (en) 2013-01-10
CN103260644A (zh) 2013-08-21
JP5890399B2 (ja) 2016-03-22
RU2545694C2 (ru) 2015-04-10
MX338052B (es) 2016-03-31
CA2798055C (en) 2015-11-24
CL2012003219A1 (es) 2013-04-05
AU2011254315B2 (en) 2015-05-14
CA2798055A1 (en) 2011-11-24
BR112012029633A8 (pt) 2017-12-05
WO2011145013A1 (en) 2011-11-24
MX2012013451A (es) 2013-01-22
EP2571521A1 (en) 2013-03-27
JP2013535953A (ja) 2013-09-19
ZA201208264B (en) 2014-01-29
NZ603431A (en) 2014-06-27
CO6670515A2 (es) 2013-05-15
AR081409A1 (es) 2012-08-29
UY33400A (es) 2011-12-30

Similar Documents

Publication Publication Date Title
CY1122872T1 (el) Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
BR112012029633A2 (pt) vetores do parapoxvírus contendo antígeno do vírus da raiva.
WO2010115133A8 (en) Newcastle disease virus vectored avian vaccines
MY157359A (en) Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes
BR112013004288A2 (pt) formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios.
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
WO2013059524A3 (en) Antibodies directed against influenza
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
AR080111A1 (es) Metodos y composiciones de inmunizacion
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
MX363149B (es) Vacunas de nucleoproteina de la influenza.
UY33523A (es) ?vectores de parapoxvirus?.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
BR112013013016A2 (pt) modulação de imunogenicidade de antígeno pela eliminação de epítopos reconhecidos pelas células nkt14
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
MX2019007924A (es) Vacunas contra la influenza.
BR112018075585A2 (pt) spv recombinante multivalente
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
BR112012029145B8 (pt) Vacina marcada para tratamento profilático da peste suína clássica, método de fabricação de uma vacina de uma cepa de vírus modificado, vivo e atenuado da peste suína clássica, e composição farmacêutica
BR112015013846A2 (pt) Composição de antígeno

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZOETIS LLC (US)

B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]